세계의 CRISPR 유전자 편집 시장 보고서(2025년)
CRISPR Gene Editing Global Market Report 2025
상품코드 : 1825691
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

CRISPR 유전자 편집 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 24.9%로 성장할 전망이며, 69억 9,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 유전성 질환의 유병률 증가, 정밀의료에 대한 중점 증가, CRISPR 연구개발 투자 증가, 노년 인구 증가, 유전자 치료 절차의 주목 증가에 기인할 것으로 보입니다. 예측 기간 주요 동향에는 유전자 편집 기술 진보, 연구수의 확대, 창약 개발, 전달 방법의 혁신, CRISPR 편집 농업의 채용 등이 포함됩니다.

향후 5년간의 성장률 24.9%라고 하는 예측은 이 시장 전회 예측으로부터 0.5%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 인상은 영국과 중국에서 공급되는 CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) 기반 치료 전달 시스템 비용을 높여 임상시험 비용을 악화시키고 정밀의료 적용을 지연시킴으로써 미국의 생명공학 기업에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

유전성 질환의 유병률 증가는 향후 수년간 CRISPR 유전자 편집 시장의 성장을 가속할 것으로 예측됩니다. 유전성 질환은 유전체의 이상으로 인한 건강 상태이며, 단일 유전자(단유전자성), 다중 유전자(다유전자성) 또는 염색체 이상의 돌연변이에 기인할 수 있습니다. 이러한 질병의 이환율 증가는 유전자 돌연변이, 인구 고령화, 근친혼 등의 요인 때문입니다. CRISPR 유전자 편집은 DNA의 정확하고 표적화된 변형을 가능하게 함으로써 유전성 질환 관리에 중요한 역할을 합니다. 과학자들은 CRISPR을 사용하여 특정 돌연변이를 확인하고 수정하고 정상적인 유전자 기능을 회복시키며 낭포성 섬유증과 겸상 적혈구 빈혈과 같은 증상을 완화합니다. 예를 들어, 2022년 7월 미국의 비영리 단체인 낭포성 섬유증(CF) 재단은 낭포성 섬유증 환자 증가를 보고하고, 미국에서는 2022년에 약 4만 명의 어린이와 성인이 앓고 있으며, 세계에서는 10만 5,000명 이상이 진단되었습니다. 따라서 유전성 질환의 유병률 증가는 CRISPR 유전자 편집 시장의 성장을 이끌고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing stands as a groundbreaking biotechnological tool that enables precise modifications to the DNA of living organisms. This technology harnesses a natural defense mechanism found in bacteria, where CRISPR sequences in DNA are utilized to identify and cut specific genetic sequences. CRISPR gene editing empowers scientists to add, remove, or alter genetic material with remarkable precision, making it a potent technique for research, therapeutic interventions, and potential treatments for genetic disorders.

The primary types of CRISPR gene editing encompass CRISPR-associated nuclease (Cas nuclease), guide RNA, DNA ligase, restriction endonuclease, and other related components. CRISPR-associated nuclease, commonly known as Cas nuclease, functions as molecular scissors, cleaving targeted DNA sequences as directed by CRISPR. This aspect focuses on the development and utilization of Cas proteins for precise gene editing, offering promising applications across industries such as agriculture, medicine, and biotechnology. It offers diverse services including design tools, plasmids, CRISPR-associated protein 9 (Cas9) and guide RNA (gRNA), delivery systems, and more. Additionally, it encompasses various technologies such as CRISPR/Cas9, zinc finger nucleases, and others, serving applications such as agriculture, biomedical research, industrial processes, genome engineering, disease modeling, functional genomics, and more. These solutions cater to a range of end users including academic institutions, research centers, biotech firms, contract research organizations (CROs), pharmaceutical companies, and biopharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The CRISPR gene editing market research report is one of a series of new reports from The Business Research Company that provides CRISPR gene editing market statistics, including the CRISPR gene editing industry global market size, regional shares, competitors with CRISPR gene editing market share, detailed CRISPR gene editing market segments, market trends, and opportunities, and any further data you may need to thrive in the CRISPR gene editing industry. These CRISPR gene editing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The crispr gene editing market size has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88 billion in 2025 at a compound annual growth rate (CAGR) of 27.1%. The growth in the historic period can be attributed to increased demand for genome editing technologies, rise in government funding, increased cancer cases, increased prevalence of chronic diseases, increased awareness about CRISPR technology, rise healthcare infrastructure.

The crispr gene editing market size is expected to see exponential growth in the next few years. It will grow to $6.99 billion in 2029 at a compound annual growth rate (CAGR) of 24.9%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, growing emphasis on precision medicine, rising investment in CRISPR research and development, increasing geriatric population, growing prominence for the gene therapy procedures. Major trends in the forecast period include advancements in gene editing technology, expansion in the number of research studies, drug discovery and development, innovation in delivery methods, adoption of CRISPR-edited agriculture.

The forecast of 24.9% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. biotech firms by driving up the cost of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR)-based therapeutic delivery systems sourced from the UK and China, exacerbating clinical trial expenses and delaying precision medicine applications. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of genetic disorders is expected to drive the growth of the CRISPR gene editing market in the coming years. Genetic disorders are health conditions caused by abnormalities in the genome, which can result from mutations in a single gene (monogenic), multiple genes (polygenic), or chromosomal abnormalities. The increasing incidence of these disorders is due to factors such as genetic mutations, aging populations, and consanguineous marriages. CRISPR gene editing plays a crucial role in managing genetic disorders by enabling precise and targeted modifications to DNA. Scientists use CRISPR to identify and correct specific mutations, restore normal gene function, and alleviate symptoms in conditions like cystic fibrosis and sickle cell anemia. For example, in July 2022, the Cystic Fibrosis (CF) Foundation, a US-based non-profit organization, reported a rise in cystic fibrosis cases, with nearly 40,000 children and adults in the United States affected in 2022, and over 105,000 people diagnosed worldwide. Therefore, the increasing prevalence of genetic disorders is driving the growth of the CRISPR gene editing market.

Major companies in the CRISPR gene editing market are focusing on developing innovative products, such as gene therapy, to expand their customer base, increase sales, and boost revenue. Gene therapy is a medical approach that uses genes to treat, prevent, or cure diseases and disorders. For example, in December 2023, the US Food and Drug Administration (FDA) approved Casgevy, a cell-based gene therapy for treating sickle cell disease. Casgevy employs CRISPR/Cas9 technology to modify hematopoietic stem cells, offering a promising treatment option for this genetic disorder.

In January 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, entered a four-year research collaboration with Beam Therapeutics. This collaboration focuses on three programs targeting rare genetic diseases affecting the liver, muscles, and central nervous system, leveraging CRISPR gene editing technology. Beam Therapeutics is a US-based biotechnology company specializing in CRISPR gene editing.

Major companies operating in the CRISPR gene editing market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., GenScript, Integrated DNA Technologies Inc., Takara Bio Inc., OriGene Technologies Inc., Intellia Therapeutics Inc., New England Biolabs, Synthego, Arbor Biotechnologies Inc., Rockland Immunochemicals Inc., Cellectis, Editas Medicine, Caribou Biosciences Inc., System Biosciences LLC, Applied StemCell, Addgene, Mirus Bio LLC, Excision BioTherapeutics Inc., GeneCopoeia Inc., ToolGen Inc., Cellecta Inc., CRISPR Therapeutics, ERS Genomics Limited

North America was the largest region in the CRISPR gene editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the CRISPR gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CRISPR gene editing market includes of revenues earned by entities by providing services such as gRNA design and vector construction, cell line and engineering, screening services, drug development services, and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR gene editing market also includes sales of gene editing vectors, laboratory equipment, kits and enzymes, libraries, design tools, antibodies, bioinformatics tools, and cell culture equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CRISPR Gene Editing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on crispr gene editing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for crispr gene editing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The crispr gene editing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. CRISPR Gene Editing Market Characteristics

3. CRISPR Gene Editing Market Trends And Strategies

4. CRISPR Gene Editing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global CRISPR Gene Editing Growth Analysis And Strategic Analysis Framework

6. CRISPR Gene Editing Market Segmentation

7. CRISPR Gene Editing Market Regional And Country Analysis

8. Asia-Pacific CRISPR Gene Editing Market

9. China CRISPR Gene Editing Market

10. India CRISPR Gene Editing Market

11. Japan CRISPR Gene Editing Market

12. Australia CRISPR Gene Editing Market

13. Indonesia CRISPR Gene Editing Market

14. South Korea CRISPR Gene Editing Market

15. Western Europe CRISPR Gene Editing Market

16. UK CRISPR Gene Editing Market

17. Germany CRISPR Gene Editing Market

18. France CRISPR Gene Editing Market

19. Italy CRISPR Gene Editing Market

20. Spain CRISPR Gene Editing Market

21. Eastern Europe CRISPR Gene Editing Market

22. Russia CRISPR Gene Editing Market

23. North America CRISPR Gene Editing Market

24. USA CRISPR Gene Editing Market

25. Canada CRISPR Gene Editing Market

26. South America CRISPR Gene Editing Market

27. Brazil CRISPR Gene Editing Market

28. Middle East CRISPR Gene Editing Market

29. Africa CRISPR Gene Editing Market

30. CRISPR Gene Editing Market Competitive Landscape And Company Profiles

31. CRISPR Gene Editing Market Other Major And Innovative Companies

32. Global CRISPR Gene Editing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CRISPR Gene Editing Market

34. Recent Developments In The CRISPR Gene Editing Market

35. CRISPR Gene Editing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기